, in development with the University of Oxford, may also generate investor concern. The biopharma firm's Phase 3 study has been kept on hold after a participant in the UK was suspected of a serious adverse reaction.
The bill aims to transfer powers previously held by the EU to regulate issues such as food standards and environment policy to the four UK nations - England, Wales, Scotland, and Northern Ireland - and to keep trade free-flowing after Brexit.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر: